

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	YTTRIUM Y 90 LABETUZUMAB
PRONUNCIATION	it' ree um la be too zoo' mab
THERAPEUTIC CLAIMS	radioimmunotherapy (RAIT) of CEA-expressing tumors for use in the treatment of colorectal cancer (monoclonal antibody)
CHEMICAL NAMES	
	(1) immunoglobulin G1, anti-(human carcinoembryonic antigen) (human-mouse monoclonal hMN-14 $\gamma$ -chain), disulfide with human-mouse monoclonal hMN-14 $\kappa$ -chain, dimer, yttrium-90Y chelate
	(2) immunoglobulin G1 (human-mouse monoclonal hMN-14 $\gamma$ -chain anti-human carcinoembryonic antigen), disulfide with human-mouse monoclonal hMN-14 $\kappa$ -chain, dimer, yttrium-90Y chelate
MOLECULAR WEIGHT	Approximately 150,000 Daltons
TRADEMARK	CEA-Cide™
MANUFACTURER	Immunomedics, Inc.
CODE DESIGNATION	<sup>90</sup> Y-hMN-14
<u>CAS</u> REGISTRY NUMBER	501423-27-4